Systemic Acne Therapy: Oral Antibiotics and Hormonal Control

When topical alone is no longer enough

Systemic therapy is a decision about severity, distribution, and scarring — not impatience. The trigger to go systemic is not simply "the creams didn't work fast enough." It is a recognizable clinical picture: moderate-to-severe inflammatory acne (papules and pustules, not just comedones); nodular or nodulocystic disease; acne on the trunk — the back, chest and shoulders — where a patient cannot realistically apply topicals to every lesion; acne that is already scarring or leaving marked pigmentation; and disease that is causing real psychological distress. In any of these, waiting longer on topicals alone risks permanent scars. The systemic drug does not replace the topical regimen from the Topical acne section — it is layered on top of it.

Oral antibiotics: killing bacteria is only half the story

The tetracyclines are the workhorses — and they treat acne through two doors at once. The first-line oral antibiotics for acne are the tetracyclines: doxycycline, lymecycline, and minocycline. Their mechanism is covered in full in the Antimicrobials chapter — they bind the bacterial 30S ribosomal subunit and block protein synthesis — and this is genuinely useful against Cutibacterium acnes (formerly Propionibacterium acnes), the organism whose overgrowth in the follicle drives inflammation. But here is the point students miss: in acne the antibiotic is not working only as an antibiotic. Tetracyclines are directly anti-inflammatory. They suppress neutrophil chemotaxis, dampen inflammatory cytokines, and inhibit matrix metalloproteinases — an effect independent of killing any bacterium. This is why very low, "sub-antimicrobial" doses of doxycycline can still improve inflammatory acne: at those doses the drug is barely touching the bacteria, yet it is still calming the inflamed follicle. The anti-inflammatory action is part of the benefit, not a side note.

The unbreakable rules: never monotherapy, never for long

An oral antibiotic for acne must obey two rules, and both exist to protect against antibiotic resistance. First, it is never given as monotherapy. It is always paired with a topical retinoid and benzoyl peroxide. Benzoyl peroxide is the key partner here: because it kills C. acnes by a non-specific oxidative mechanism, bacteria cannot become resistant to it, and using it alongside the antibiotic dramatically slows the emergence of resistant strains. The retinoid, meanwhile, unblocks the follicle and treats the comedones the antibiotic ignores. Second, the antibiotic is a limited course, not a maintenance drug — typically three to four months, reassessed and then stopped, with the topical retinoid carried on for long-term maintenance. Prolonged, repeated, or solo antibiotic use is exactly how a patient — and a community — grows resistant C. acnes, an issue the Antimicrobials chapter frames as antibiotic stewardship. Every course you keep short is a course of resistance you prevent.

Every tetracycline shares a set of cautions — and minocycline adds its own. As a class, tetracyclines cause photosensitivity — patients burn more easily and should use sun protection, which matters for a young population outdoors in summer. Taken carelessly they can cause pill oesophagitis, so they are swallowed with plenty of water and the patient stays upright afterwards. They are firmly contraindicated in pregnancy and in children under eight, because they bind calcium in developing teeth and bone and cause permanent tooth staining and enamel defects. Minocycline stands slightly apart within the class: it is more lipophilic and, though sometimes effective when others fail, it carries rarer but serious idiosyncratic reactions the others largely do not — a drug-induced lupus-like syndrome, a slate-grey skin and mucosal hyperpigmentation, and the severe multi-organ hypersensitivity reaction DRESS (drug reaction with eosinophilia and systemic symptoms). For this reason many guidelines favour doxycycline or lymecycline first and reserve minocycline.

One group cannot take a tetracycline at all: pregnant women and young children. For them the alternative oral antibiotic is a macrolide — usually erythromycin. Its mechanism, binding the 50S ribosomal subunit, is again detailed in the Antimicrobials chapter. Erythromycin is a reasonable substitute here precisely because it is one of the safer antibiotics in pregnancy, but C. acnes resistance to macrolides is common and rising, so the same stewardship rules apply — pair it with benzoyl peroxide, keep the course short, and never run it as monotherapy.

Hormonal therapy in women: draining the gland at its source

Acne is, at root, an androgen-driven disease of the sebaceous gland — so in women you can treat the driver directly. Androgens enlarge the sebaceous gland and drive it to pump out sebum — the raw material acne is built from. In women (this approach does not apply to men, for obvious reasons) you can turn that driver down with hormonal therapy, and it often works where antibiotics have failed, particularly for hormonal-pattern acne along the jaw and lower face that flares with the menstrual cycle. There are two levers. The first is the combined oral contraceptive pill. Its oestrogen component raises sex-hormone-binding globulin (SHBG), the protein that mops up circulating testosterone; more SHBG means less free, active androgen reaching the gland. Less androgen signal, less sebum. The second lever is spironolactone.

Spironolactone is best known from the Endocrine & Cardiovascular chapters as an aldosterone antagonist — a potassium-sparing diuretic. But it is also an androgen-receptor blocker, and at the sebaceous gland that second action is the useful one: it stands in the doorway of the androgen receptor and reduces the androgen signal that tells the gland to make sebum. Both hormonal options share one crucial teaching point about timing: they are slow. Where a nodule might visibly settle within weeks of starting an antibiotic, hormonal therapy needs a patient three-plus months to show its full effect. It is not a rescue drug; it is a strategy. That slow, steady sebum-suppression, though, is exactly why it can succeed after antibiotics fade.

Each hormonal lever comes with its own monitoring — most of it inherited from its cardiovascular and reproductive pharmacology. For spironolactone, the two things to watch flow straight from its other lives as a drug. Because it spares potassium, it can cause hyperkalaemia — a concern to keep in mind, especially with other potassium-raising drugs, though serious rises are uncommon in otherwise healthy young women. And because it blocks androgen receptors indiscriminately, it must not be used in pregnancy: an anti-androgen given during pregnancy risks feminising the genitalia of a male fetus. So it is prescribed with reliable contraception, which is one reason it pairs naturally with the combined pill. The combined oral contraceptive carries its own familiar cautions — chiefly the raised risk of venous thromboembolism, and unsuitability in women with migraine-with-aura or other vascular risk factors, all covered in the reproductive pharmacology teaching. Matched to the right woman, though, hormonal therapy treats acne at a level no antibiotic reaches: the sebaceous gland itself.

When to skip ahead to isotretinoin

Systemic antibiotics and hormonal therapy are the middle of the ladder, not the top. Some acne earns a jump straight past them to oral isotretinoin — the single most effective acne drug, and the subject of its own Isotretinoin chapter. Reach for it when the disease is severe from the outset (nodulocystic or conglobate acne), when it is scarring despite appropriate treatment, when it relapses quickly every time antibiotics stop, or when it is inflicting serious psychological harm. Isotretinoin is the only acne drug that acts on all four causes at once and can produce a lasting remission rather than mere control. The trade-off is a demanding safety profile — above all its powerful teratogenicity, requiring strict pregnancy prevention — which is why it has a chapter to itself. The clinical skill is recognising the patient who should not spend a year cycling through antibiotics before getting there.